Founded in 2015, Amcarelab provides clinical genetic services including genetic disease diagnosis and treatment consulting. It is a biomedical enterprise with the development and production of in vitro diagnostic kits and clinical testing services.
Amcarelab (Chinese: 嘉检医学)completed the Series B+ financing round worth nearly CNY 200 million (USD 29.92 million). This round of financing was led by CICC Qide (Chinese: 中金启德基金), followed by Bison Capital (Chinese: 贝森医疗基金), Technology Financial Group (Chinese: 粤科金融集团) and Jointown Medical Investment (Chinese: 九州通创投).
The fund will be mainly used for the R&D and registration of detection reagent pipelines, continue to improve the construction of closed-loop supply chains in the genomic disease diagnosis and promote the industrial upgrading of the genomic diseases.
As a third-party medical testing laboratory focusing on clinical genetic disease diagnosis, Amcarelab provides healthcare institutions with molecular detection instruments, reagents, and software, as well as clinical training, hospital consultation, and personalized genetic counseling.
With the rapid development of genome, stem cells, CRISPR (a technology that can be used to edit genes), and other related biotechnology, our understanding of the etiology of human diseases has been greatly improved. In this case, the clinical demand for gene detection and diagnosis is growing, especially in the context of the ending of China's population control. The screening and diagnosis of genetic diseases can effectively reduce the birth defects and the burden on families and society caused by this.
At present, the companies providing genetic testing services include BGI (Chinese: 华大基因), BerryGenomics (Chinese: 贝瑞基因), DAAN Gene (Chinese: 达安基因), and CapitalBio Gene (Chinese: 博奥基因).